Affiliation:
1. Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania
Abstract
ABSTRACT
Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 μg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 μg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were ≤4.0 μg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference25 articles.
1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. Antimicrob. Agents Chemother.41:2795-2796.
2. Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureus
3. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus isolated at Hershey Medical Center. J. Antimicrob. Chemother.52:864-868.
4. Candiani, G., M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother.44:179-192.
5. Cercenado, E., F. Garcia-Garrote, and E. Bouza. 2001. In-vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother.47:77-81.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献